Efficacy and safety of Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis: Results from the Phase 3 IMMvent trial

被引：0
|
作者：
Reich, K. [1 ,2 ]
Gooderham, M. [3 ,4 ]
Thaci, D. [5 ]
Crowley, J. J. [6 ]
Ryan, C. [7 ]
Kruger, J. G. [8 ]
Tsai, T. [9 ]
Flack, M. [10 ]
Gu, Y. [11 ]
Williams, D. A. [11 ]
Thompson, E. H. [11 ]
Paul, C. [12 ,13 ]
机构：
[1] ISCIderm Res Inst, Berlin, Germany
[2] Dermatologikum, Berlin, Germany
[3] Queens Univ, Kingston, ON, Canada
[4] Ctr Dermatol & Prob Med Res, Kingston, ON, Canada
[5] Univ Lubeck, Lubeck, Germany
[6] Bakersfield Dermatol, Bakersfield, CA USA
[7] Univ Coll Dublin, Dublin, Ireland
[8] Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA
[9] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[10] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[11] AbbVie Inc, Chicago, IL USA
[12] Paul Sabatier Univ, Toulouse, France
[13] Larrey Hosp, Toulouse, France
来源：
EXPERIMENTAL DERMATOLOGY | 2019年 / 28卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P051
引用
收藏
页码：E24 / E25
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of risankizumab (RZB) compared with adalimumab (ADA) in patients with moderate-to-severe plaque psoriasis: results from the phase 3 IMMvent trial
    Reich, K.
    Gooderham, M.
    Thaci, D.
    Crowley, J. J.
    Ryan, C.
    Krueger, J. G.
    Tsai, T. -F.
    Flack, M.
    Gu, Y.
    Williams, D. A.
    Thompson, E. H. Z.
    Paul, C.
    EXPERIMENTAL DERMATOLOGY, 2018, 27 : 9 - 10
  • [2] Efficacy and safety of continuous risankizumab or switching from adalimumab to risankizumab treatment in patients with moderate-to-severe plaque psoriasis: Results from the phase 3 IMMvent Trial
    Reich, Kristian
    Gooderham, Melinda
    Thaci, Diamant
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB52 - AB52
  • [3] Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
    Reich, Kristian
    Gooderham, Melinda
    Thaci, Diamant
    Crowley, Jeffrey J.
    Ryan, Caitriona
    Krueger, James G.
    Tsai, Tsen-Fang
    Flack, Mary
    Gu, Yihua
    Williams, David A.
    Thompson, Elizabeth H. Z.
    Paul, Carle
    LANCET, 2019, 394 (10198): : 576 - 586
  • [4] Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis
    Ryan, C.
    Crowley, J.
    Valdecantos, W.
    Wu, T.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 20 - 21
  • [5] Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis
    Ryan, Caitriona
    Crowley, Jeffrey
    Valdecantos, Wendell
    Wu, Tianshuang
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB55 - AB55
  • [6] Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial
    Ohtsuki, Mamitaro
    Fujita, Hideki
    Watanabe, Mitsunori
    Suzaki, Keiko
    Flack, Mary
    Huang, Xin
    Kitamura, Susumu
    Valdes, Joaquin
    Igarashi, Atsuyuki
    JOURNAL OF DERMATOLOGY, 2019, 46 (08): : 686 - 694
  • [7] Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial (vol 394, pg 576, 2019)
    Reich, K.
    Gooderham, M.
    Thaci, D.
    LANCET, 2019, 394 (10198): : 564 - 564
  • [8] RISANKIZUMAB EFFICACY/SAFETY IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 16-WEEK RESULTS FROM IMMHANCE
    Blauvelt, Andrew
    Papp, Kim A.
    Gooderham, Melinda
    Langley, Richard G.
    Leonardi, Craig
    Lacour, Jean-Philippe
    Philipp, Sandra
    Tyring, Stephen
    Bukhalo, Michael
    Wu, Jashin J.
    Bagel, Jerry
    Frankel, Ellen H.
    Pariser, David
    Flack, Mary
    Scherer, Joseph
    Geng, Ziqian
    Gu, Yihua
    Camez, Anne
    Thompson, Elizabeth H. Z.
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 30 - 30
  • [9] Risankizumab in moderate-to-severe plaque psoriasis
    Serrano, Linda
    Maloney, Victoria
    Gordon, Kenneth B.
    IMMUNOTHERAPY, 2019, 11 (16) : 1357 - 1370
  • [10] Efficacy of Risankizumab compared with placebo across subgroups in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials
    Lebwohl, M.
    Ghislain, P.
    Kerdel, F.
    Gu, Y.
    Valdes, J. M.
    Thompson, E. H.
    Lynde, C.
    EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E25 - E25
12345